• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

接种物、pH 值和阳离子对 fidaxomicin（OPT-80，PAR-101）体外抗艰难梭菌活性的影响。

Effects of inoculum, pH, and cations on the in vitro activity of fidaxomicin (OPT-80, PAR-101) against Clostridium difficile.

机构信息

Department of Biology, Optimer Pharmaceuticals, Inc., San Diego, CA 92121, USA.

出版信息

Antimicrob Agents Chemother. 2010 Jun;54(6):2674-6. doi: 10.1128/AAC.01842-09. Epub 2010 Mar 22.

DOI:10.1128/AAC.01842-09
PMID:20308366
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2876407/
Abstract

The effects of the inoculum, pH, cation concentrations, and different lots of commercial media on the in vitro susceptibility of Clostridium difficile to fidaxomicin were examined. Of the factors evaluated, only pH alterations influenced the activity of fidaxomicin against C. difficile, noticeably reducing its activity at higher pH (> or =7.9).

摘要

检测了接种物、pH 值、阳离子浓度和不同批次商业培养基对艰难梭菌体外对非达霉素敏感性的影响。在所评估的因素中，只有 pH 值的改变影响了非达霉素对艰难梭菌的活性，在较高的 pH 值（≥7.9）时明显降低了其活性。

相似文献

1
Effects of inoculum, pH, and cations on the in vitro activity of fidaxomicin (OPT-80, PAR-101) against Clostridium difficile.接种物、pH 值和阳离子对 fidaxomicin（OPT-80，PAR-101）体外抗艰难梭菌活性的影响。
Antimicrob Agents Chemother. 2010 Jun;54(6):2674-6. doi: 10.1128/AAC.01842-09. Epub 2010 Mar 22.
2
In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile.OPT-80 针对产毒素艰难梭菌临床分离株的体外活性。
Antimicrob Agents Chemother. 2008 Nov;52(11):4163-5. doi: 10.1128/AAC.00476-08. Epub 2008 Aug 25.
3
Antimicrobial activities of fidaxomicin. fidaxomicin 的抗菌活性。
Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S143-8. doi: 10.1093/cid/cis339.
4
Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.LFF571 对艰难梭菌和 630 株其他需氧和厌氧肠道菌株的体外比较活性。
Antimicrob Agents Chemother. 2012 May;56(5):2493-503. doi: 10.1128/AAC.06305-11. Epub 2012 Jan 30.
5
Fidaxomicin: a review of its use in patients with Clostridium difficile infection.非达霉素：用于治疗艰难梭菌感染患者的综述。
Drugs. 2013 Oct;73(15):1733-47. doi: 10.1007/s40265-013-0134-z.
6
Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores.非达霉素和万古霉素均可抑制艰难梭菌孢子的生长。
Antimicrob Agents Chemother. 2013 Jan;57(1):664-7. doi: 10.1128/AAC.01611-12. Epub 2012 Nov 12.
7
Fidaxomicin: in Clostridium difficile infection.非达霉素：治疗艰难梭菌感染。
Drugs. 2011 Dec 24;71(18):2445-56. doi: 10.2165/11208220-000000000-00000.
8
Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. fidaxomicin 和其主要代谢产物 OP-1118 对艰难梭菌的抗生素后效应。
Antimicrob Agents Chemother. 2011 Sep;55(9):4427-9. doi: 10.1128/AAC.00104-11. Epub 2011 Jun 27.
9
Analysis of Clostridium difficile biofilms: imaging and antimicrobial treatment.艰难梭菌生物膜分析：成像与抗菌治疗。
J Antimicrob Chemother. 2018 Jan 1;73(1):102-108. doi: 10.1093/jac/dkx353.
10
Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection.两项关于 fidaxomicin 治疗艰难梭菌感染的 III 期临床试验中，收集的基线、复发和失败时患者分离株对 fidaxomicin（OPT-80）的比较药敏性。
Antimicrob Agents Chemother. 2011 Nov;55(11):5194-9. doi: 10.1128/AAC.00625-11. Epub 2011 Aug 15.

引用本文的文献

1
Fidaxomicin's Role in Overcoming Vancomycin Failure in Clostridium difficile Infections: A Case Series and Literature Review.非达霉素在克服艰难梭菌感染中万古霉素治疗失败的作用：病例系列及文献综述
Cureus. 2025 Mar 24;17(3):e81110. doi: 10.7759/cureus.81110. eCollection 2025 Mar.
2
Formal Single Atom Editing of the Glycosylated Natural Product Fidaxomicin Improves Acid Stability and Retains Antibiotic Activity.糖基化天然产物非达霉素的形式单原子编辑提高了酸稳定性并保留了抗生素活性。
JACS Au. 2024 May 21;4(6):2267-2280. doi: 10.1021/jacsau.4c00206. eCollection 2024 Jun 24.
3
Fidaxomicin vs Vancomycin for the Treatment of a First Episode of Clostridium Difficile Infection: A Meta-analysis and Systematic Review.非达霉素与万古霉素治疗艰难梭菌感染初发 episode：一项荟萃分析与系统评价
Cureus. 2018 Jun 11;10(6):e2778. doi: 10.7759/cureus.2778.
4
Nitroimidazole carboxamides as antiparasitic agents targeting Giardia lamblia, Entamoeba histolytica and Trichomonas vaginalis.硝基咪唑甲酰胺作为针对蓝氏贾第鞭毛虫、溶组织内阿米巴和阴道毛滴虫的抗寄生虫药物。
Eur J Med Chem. 2016 Sep 14;120:353-62. doi: 10.1016/j.ejmech.2016.04.064. Epub 2016 Apr 27.
5
Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection.非达霉素：一种治疗艰难梭菌感染的新型药物。
Can J Infect Dis Med Microbiol. 2015 Nov-Dec;26(6):305-12. doi: 10.1155/2015/934594.
6
Fidaxomicin: a review of its use in patients with Clostridium difficile infection.非达霉素：用于治疗艰难梭菌感染患者的综述。
Drugs. 2013 Oct;73(15):1733-47. doi: 10.1007/s40265-013-0134-z.
7
Antimicrobial activities of fidaxomicin. fidaxomicin 的抗菌活性。
Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S143-8. doi: 10.1093/cid/cis339.
8
Fidaxomicin: in Clostridium difficile infection.非达霉素：治疗艰难梭菌感染。
Drugs. 2011 Dec 24;71(18):2445-56. doi: 10.2165/11208220-000000000-00000.

本文引用的文献

1
Clostridium difficile infections: emerging epidemiology and new treatments.艰难梭菌感染：新出现的流行病学及新的治疗方法
J Pediatr Gastroenterol Nutr. 2009 Apr;48 Suppl 2:S63-5. doi: 10.1097/MPG.0b013e3181a118c6.
2
Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006.2001 - 2006年美国儿童医院住院患者艰难梭菌相关疾病的流行病学特征
Pediatrics. 2008 Dec;122(6):1266-70. doi: 10.1542/peds.2008-0469.
3
Community-onset Clostridium difficile-associated diarrhoea not associated with antibiotic usage--two case reports with review of the changing epidemiology of Clostridium difficile-associated diarrhoea.社区获得性艰难梭菌相关性腹泻，与抗生素使用无关——两例病例报告并回顾艰难梭菌相关性腹泻不断变化的流行病学情况
Neth J Med. 2008 May;66(5):207-11.
4
Update of Clostridium difficile-associated disease due to PCR ribotype 027 in Europe.欧洲027型聚合酶链反应核糖体分型艰难梭菌相关疾病的最新情况
Euro Surveill. 2007 Jun 1;12(6):E1-2. doi: 10.2807/esm.12.06.00714-en.
5
An epidemic, toxin gene-variant strain of Clostridium difficile.一种艰难梭菌的流行、毒素基因变异菌株。
N Engl J Med. 2005 Dec 8;353(23):2433-41. doi: 10.1056/NEJMoa051590. Epub 2005 Dec 1.
6
A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.艰难梭菌相关性腹泻的多机构主要克隆性暴发，发病率和死亡率高。
N Engl J Med. 2005 Dec 8;353(23):2442-9. doi: 10.1056/NEJMoa051639. Epub 2005 Dec 1.
7
In vitro activities of OPT-80 and comparator drugs against intestinal bacteria.OPT-80及对照药物对肠道细菌的体外活性。
Antimicrob Agents Chemother. 2004 Dec;48(12):4898-902. doi: 10.1128/AAC.48.12.4898-4902.2004.
8
Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species.新型大环化合物OPT-80与其他八种药物针对特定厌氧菌种的活性比较。
Antimicrob Agents Chemother. 2004 Nov;48(11):4430-4. doi: 10.1128/AAC.48.11.4430-4434.2004.
9
Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity.1991年至2003年魁北克某地区艰难梭菌相关性腹泻：疾病严重程度的变化模式
CMAJ. 2004 Aug 31;171(5):466-72. doi: 10.1503/cmaj.1041104.
10
In vitro activity of OPT-80 against Clostridium difficile.OPT-80对艰难梭菌的体外活性。
Antimicrob Agents Chemother. 2004 Jun;48(6):2280-2. doi: 10.1128/AAC.48.6.2280-2282.2004.